The European Commission announced on Thursday that it has imposed fines totaling 13.4 million euros (approximately $14.1 million) on five pharmaceutical companies, marking the conclusion of their antitrust investigation.
The Commission levied penalties on Alkaloids of Australia, Alkaloids Corporation, Boehringer, Linnea, and Transo-Pharm for their involvement in a cartel that aimed to manipulate the minimum price of a crucial ingredient used in the production of abdominal antispasmodic drugs.
The substance at the center of this cartel was identified as N-Butylbromide Scopolamine/Hyoscine, referred to as ‘SNBB.’ SNBB serves as a vital component in the manufacturing of the abdominal antispasmodic drug Buscopan and its generic variations.
The Commission’s extensive investigation brought to light that these six companies had cooperated in fixing the minimum sales price of SNBB for their customers, which primarily included distributors and generic drug manufacturers. Additionally, they had engaged in the allocation of quotas and exchanged commercially sensitive information.
Read more: Pharma Giant Charged With Price-Fixing In Generics Probe
The fines imposed on these pharmaceutical companies were determined in line with the Commission’s 2006 Guidelines on fines. These guidelines provide a structured framework for calculating penalties in cases of antitrust violations.
The Commission considered various factors when setting the fines, including the value of SNBB sales associated with the violation, the complexity and multifaceted nature of the antitrust infringement, the geographic extent of the cartel’s operations, and the duration of their illicit activities.
Source: Reuters
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI